Pharmacogenomics Market (2026-2036)

The growth of this market is mainly driven by the expansion of pharmacogenomic information in drug labelling to 217 drugs across regulatory tables and consortium guidelines, the first United States label requirement for pre-treatment DPYD genotyping in a widely prescribed chemotherapy, randomised evidence that a 12-gene panel reduces clinically relevant adverse drug reactions by approximately 30%, an ageing population managed on polypharmacy, electronic health record integration of clinical decision support, and national panel testing programmes in Europe. However, uneven commercial reimbursement, falling revenue per test, limited clinician awareness and ordering confidence, the absence of a settled regulatory pathway for laboratory developed tests, and the under-representation of non-European ancestries in variant evidence restrain the growth of this market.

Beyond these, pre-emptive multi-gene panel testing, DPYD and other mandated single-gene assays, artificial intelligence applied to variant interpretation and prescribing decision support, point-of-care genotyping, and national genomic medicine programmes are expected to create significant growth opportunities for the stakeholders in this market.

Pharmacogenomics is the study and clinical application of how inherited genetic variation alters the way an individual absorbs, metabolises, transports and responds to medicines, applied to select the right drug and the right dose and to avoid adverse drug reactions. The market comprises the consumables, instruments, software and services used to generate, interpret and act on that information. Consumables include assay kits, reagents, probes, primers, arrays and library preparation chemistry; instruments include real-time thermal cyclers, sequencers, microarray scanners, mass spectrometers and electrophoresis systems; software and services include variant calling and interpretation pipelines, clinical decision support integrated with electronic prescribing, reporting platforms and laboratory testing services. Clinically the market spans both reactive testing at the point of prescription, such as DPYD genotyping before a fluoropyrimidine, and pre-emptive panel testing in which 12 or more genes are genotyped in advance and results are stored for future prescribing decisions. On this basis the market was valued at USD 10.80 billion in 2024 and USD 11.70 billion in 2025, is estimated at USD 12.70 billion in 2026 and is forecast to reach USD 29.90 billion by 2036 at a CAGR of 8.9%, with consumables representing 71.5% of 2026 value. Companion diagnostics for somatic tumour mutations, drug discovery target identification and consumer ancestry testing fall outside this scope.

The ecosystem connects four groups that do not share an economic model. Technology suppliers provide sequencers, polymerase chain reaction platforms, microarrays, mass spectrometry systems and the consumables that run on them, earning recurring revenue from the 71.5% of market value represented by consumables in 2026. Testing providers, comprising hospital laboratories, reference laboratories and specialist pharmacogenomic laboratories, convert that capacity into reported results and carry the reimbursement risk. Knowledge and software providers maintain variant databases, translate genotype to phenotype, and embed prescribing recommendations into electronic health records, drawing on the Clinical Pharmacogenetics Implementation Consortium, the Dutch Pharmacogenetics Working Group and regulatory tables that together cover 217 drugs. Clinical users comprise prescribing physicians, oncologists, psychiatrists, clinical pharmacists and genetic counsellors, with pharmacists increasingly operating consultation services. Payers, including commercial insurers, Medicare administrative contractors and national health systems, determine whether any of it is ordered at scale.

Four platform families divide this market and are moving at different speeds. Polymerase chain reaction remains the largest technology at 39.5% of 2026 value because targeted genotyping of a known actionable variant such as DPYD, HLA-B*57:01 or CYP2C19 is fast, inexpensive and well suited to the reactive, single-drug testing that reimbursement supports. Sequencing is the fastest-growing at an 11.4% CAGR, because pre-emptive panels require simultaneous interrogation of 50 or more germline variants across 12 or more genes, which short-read and long-read sequencing deliver at declining cost per sample, and because structurally complex loci such as CYP2D6, with copy number variation and hybrid alleles, are poorly resolved by targeted assays. Microarrays retain a position in fixed-content panel testing at high throughput. Mass spectrometry supports multiplexed genotyping and therapeutic drug monitoring, and electrophoresis supports fragment analysis. Artificial intelligence is being applied to variant interpretation, phenotype assignment and prescribing decision support rather than to detection.

Three regulatory streams govern this market and they are not aligned. Drug labelling is expanding: the capecitabine label was updated in October 2025, with the agency letter dated 3 October 2025, to call for DPYD genetic testing before initiating treatment unless urgent, matching the European Medicines Agency recommendation of 30 April 2020 covering intravenous fluorouracil, capecitabine and tegafur, under which complete dihydropyrimidine dehydrogenase deficiency is a contraindication and partial deficiency requires a reduced starting dose. Guideline bodies are expanding faster still, with 217 drugs carrying pharmacogenomic information across the regulatory table, consortium guidelines or both as of 22 July 2024. Test regulation, by contrast, contracted: the laboratory developed tests final rule was vacated on 31 March 2025 in American Clinical Laboratory Association v. U.S. Food and Drug Administration, No. 4:24-CV-479, in the Eastern District of Texas, on the ground that the agency exceeded its statutory authority, removing from medical device oversight nearly 80,000 tests offered by almost 1,200 laboratories ahead of a May 2025 effective date and leaving clinical laboratory improvement requirements as the governing framework. European in vitro diagnostic regulation applies a separate conformity assessment regime to assays placed on that market.

North America holds the largest position at 41.4% of 2026 value, led by the U.S., supported by the depth of the reference laboratory sector, the October 2025 capecitabine labelling requirement, health system implementation programmes and the removal of a device pathway for laboratory developed tests, offset by commercial coverage restrictions effective from 1 January 2025. Europe holds 31.0%, with Germany the largest country market, and leads on systematic implementation: the European Medicines Agency mandated dihydropyrimidine dehydrogenase testing from 30 April 2020, and the PREPARE study was conducted across seven European countries under Dutch Pharmacogenetics Working Group recommendations. Asia-Pacific is projected to register the highest CAGR at 10.1%, led by China at 11.3%, supported by domestic sequencing capacity, national precision medicine programmes and allele frequencies that differ materially from European reference populations. Latin America holds 4.7%, with Brazil representing 59.3% of the region, and the Middle East & Africa holds 2.5%, with Saudi Arabia representing 33.2% of the region, both driven by tertiary oncology capacity and national genome programmes.

The addressable prescribing base has widened from a handful of oncology agents to routine primary care medicines. As of 22 July 2024, 217 drugs carried pharmacogenomic information in the Food and Drug Administration table of pharmacogenetic associations, in Clinical Pharmacogenetics Implementation Consortium guidelines, or in both, comprising 103 in consortium guidelines only, 64 in the regulatory table only and 50 in both, so consortium guidance covers 153 drugs and the regulatory table 114. The clinical significance is the composition rather than the count: the drugs most frequently encountered in pre-emptive testing are statins, antiplatelets and immunosuppressants, with atorvastatin, clopidogrel and tacrolimus the three most common index drugs in the PREPARE study at 716, 619 and 472 patients respectively. Each addition converts a discretionary test into a prescribing input, and because the two sources often assign different gene associations or dosing implications to the same drug, each also creates demand for interpretation software.

Mandated testing produces volume that awareness campaigns do not. The capecitabine label was updated in October 2025, with the Food and Drug Administration letter dated 3 October 2025, to call for DPYD genetic testing before initiating treatment unless treatment is urgent. Approximately 7% of patients are estimated to be poor metabolisers, for whom no safe starting dose of capecitabine or fluorouracil has been established, while intermediate metabolisers can begin at a reduced dose and titrate upward as tolerated. Most results return within about a week when the test is ordered during treatment planning, which makes the requirement operationally feasible in routine oncology scheduling. Because capecitabine and fluorouracil are among the most widely prescribed cytotoxic agents in gastrointestinal, breast and head and neck cancer, a single label change converts a large and recurring prescribing population into a testing population, and it does so in the application segment that already holds 36.0% of 2026 market value.

The European requirement predates the United States action by five years and demonstrates durability rather than novelty. The European Medicines Agency issued its recommendation on 30 April 2020, after a review initiated in March 2019 at the request of the French medicines agency, covering fluorouracil given by injection or infusion and the oral prodrugs capecitabine and tegafur, with testing by phenotype through measurement of blood uracil levels and by genotyping of the dihydropyrimidine dehydrogenase gene. Up to 9% of the Caucasian population carry partial enzyme deficiency and up to 0.5% lack the enzyme entirely, for whom these medicines are contraindicated, while partial deficiency requires consideration of a reduced starting dose. Two direct healthcare professional communications were issued and the committee opinion passed to the European Commission for a legally binding decision applicable across all member states, which is why European implementation is systematic rather than institution by institution.

Pre-emptive panel testing now has a randomised implementation result rather than observational support. The PREPARE study, an open-label, multicentre, cluster-randomised crossover implementation study across seven European countries, enrolled 6,944 adults starting a first prescription for an index drug carrying an actionable Dutch Pharmacogenetics Working Group recommendation, with 3,342 allocated to genotype-guided prescribing and 3,602 to standard care, and tested 50 germline variants across 12 genes. 93.5% of participants carried at least one actionable variant. Clinically relevant adverse drug reactions within 12 weeks fell from 28.6% to 21.5%, an odds ratio of 0.70 with a 95% confidence interval of 0.61 to 0.79 and a p value below 0.0001, equivalent to an approximately 30% relative reduction and about 7 percentage points absolute. In the actionable-result subgroup the rates were 21% against 27.7%, odds ratio 0.70 with a confidence interval of 0.54 to 0.91.

The value of a pharmacogenomic result rises with the number of medicines a patient takes, because each additional prescription multiplies the probability of encountering an actionable gene-drug pair. In the PREPARE cohort 93.5% of participants carried at least one actionable variant across just 12 genes and 50 variants, so in a population taking 5 or more chronic medicines the probability that at least one prescription is affected approaches certainty. The therapeutic areas where this concentrates are precisely those with the largest shares of this market: oncology at 36.0% of 2026 value, alongside cardiology, mental health and neurological disorders, where statins, antiplatelets, antidepressants, antipsychotics and anticonvulsants all carry actionable associations. Health system implementation data illustrate the yield: one United States system requiring DPYD testing since 2022 reported more than 5,000 oncology tests, 929 critical pharmacogenomic safety alerts, 154 medication changes that prevented serious harm and more than 800 consultations.

The most consequential commercial development of the base period moved against the fastest-growing test format. UnitedHealthcare notified Myriad Genetics on 1 November 2024 of a medical policy update restricting access to multi-gene panel pharmacogenetic testing under its commercial and individual exchange benefit plans with effect from 1 January 2025, citing insufficient evidence of efficacy. The affected GeneSight psychotropic test covers more than 60 medications used in depression, anxiety, attention deficit hyperactivity disorder and other psychiatric conditions and had been ordered by tens of thousands of clinicians for almost three million patients, with Medicare Advantage and managed Medicaid coverage understood to be unaffected. The structural problem is that the randomised evidence supporting panels, including the PREPARE odds ratio of 0.70, is an implementation outcome rather than a drug-specific efficacy endpoint, which payer evidence frameworks built for therapeutics are not designed to credit.

The commercial pattern in this market is now rising volume against falling price, which decouples unit growth from value growth. Myriad Genetics reported second-quarter 2026 Mental Health revenue of USD 36.8 million, down 3%, on volumes of 140 thousand tests, up 4%, with average revenue per test down 6% reflecting a write-off of aged receivables. Group revenue fell 11% to USD 190.7 million on total volumes of 379 thousand, down 1%, with group average revenue per test down 9% including an USD 11.0 million reduction from changes in estimates of cash collections on prior-period tests. Adjusted gross margin fell from 71.5% to 66.9%, adjusted EBITDA moved from positive USD 14.5 million to negative USD 16.9 million, full-year revenue guidance was cut to USD 770 million to USD 790 million and adjusted EBITDA guidance was suspended, with management citing increased payer friction.

A result that is not acted on generates no clinical benefit and no repeat demand. In the PREPARE study, conducted in specialist centres with protocol support and embedded decision tools, only 69.9% of Dutch Pharmacogenetics Working Group recommendations were accepted, and the primary analysis was conducted regardless of adherence to those recommendations. If acceptance is approximately 70% under trial conditions, acceptance in unsupported routine practice is lower. The underlying constraints are that prescribers are not trained to interpret diplotype nomenclature, that genotype-to-phenotype translation differs between the regulatory table and consortium guidelines for the 50 drugs listed in both, and that a result returned after a prescription has been written rarely changes it. This is why software and clinical decision support, rather than assay chemistry, is the segment on which implementation depends, and why pharmacist-led consultation services have become the operational model in systems that have made testing work.

Most pharmacogenomic testing is delivered as a laboratory developed test, and the regulatory framework for that category was removed rather than clarified. In American Clinical Laboratory Association v. U.S. Food and Drug Administration, No. 4:24-CV-479, the United States District Court for the Eastern District of Texas vacated the laboratory developed tests final rule on 31 March 2025, holding that the agency had exceeded its statutory authority and relying on the removal of judicial deference to agency statutory interpretation. The rule would have brought nearly 80,000 existing tests offered by almost 1,200 laboratories within medical device regulation from a May 2025 effective date. The vacatur reduces near-term compliance cost but leaves analytical and clinical validity governed by clinical laboratory improvement requirements alone, which assess laboratory process rather than clinical claim. For payers evaluating whether to cover a panel, the absence of a device review is itself an argument against coverage.

The evidence base that underpins guidelines and labelling was generated predominantly in European-ancestry populations, which limits its transferability to the fastest-growing regional market. In the PREPARE study, 97.7% of the cohort was of European, Mediterranean or Middle Eastern ancestry, a limitation the investigators acknowledged. This matters because allele frequencies for the principal pharmacogenes differ substantially between populations: CYP2C19 loss-of-function frequencies are materially higher in East and South Asian populations than in European populations, HLA-B*15:02 is concentrated in Southeast Asian populations, and NUDT15 variants relevant to thiopurine dosing are more common in East Asian populations. Asia-Pacific is projected to grow fastest at a 10.1% CAGR, led by China at 11.3%, yet panel content and phenotype assignment algorithms optimised for European allele distributions will under-detect actionable variants there, which creates both a scientific gap and a commercial requirement for regionally designed panels.

The structural opportunity is to move testing from the point of prescription to the point of enrolment, so that a single test informs decades of prescribing. The clinical case is established, with the PREPARE study recording a fall in clinically relevant adverse drug reactions from 28.6% to 21.5% at an odds ratio of 0.70 across 6,944 patients in seven countries using 50 variants in 12 genes, and with 93.5% of participants carrying at least one actionable variant. The economic case follows from amortisation: one genotyping event, priced once, serves every subsequent prescription, which converts a per-prescription cost into a one-time population investment. National health systems are the natural buyers because they capture the downstream savings, and European systems operating under Dutch Pharmacogenetics Working Group recommendations have demonstrated the implementation pathway. For suppliers the opportunity is panel content, result storage and lifelong decision support rather than repeat assay sales.

Mandated tests are the only part of this market with assured volume and settled reimbursement logic, and the mandate list is growing. DPYD genotyping before fluoropyrimidine therapy is now called for in United States labelling from October 2025 and has been required in Europe since 30 April 2020, covering intravenous fluorouracil, capecitabine and tegafur, with approximately 7% of patients poor metabolisers in the United States framing and up to 9% carrying partial deficiency and up to 0.5% complete deficiency in the European framing. Comparable mandated or strongly recommended single-gene assays include HLA-B*57:01 before abacavir, HLA-B*15:02 before carbamazepine, TPMT and NUDT15 before thiopurines, UGT1A1 before irinotecan and G6PD before rasburicase. Each is a targeted polymerase chain reaction test, which is why that technology retains 39.5% of 2026 value, and each carries a clear clinical consequence that payers find easier to credit than a panel.

The unsolved problem in this market is interpretation rather than detection, which is where artificial intelligence has a defensible application. Three specific gaps exist. First, genotype-to-phenotype assignment is inconsistent, with the regulatory table and consortium guidelines assigning different gene associations or dosing implications to the same drug among the 50 listed in both sources. Second, structurally complex loci such as CYP2D6, which carries copy number variation, gene deletions and hybrid alleles, require computational resolution that targeted assays cannot provide. Third, recommendation acceptance was only 69.9% even under PREPARE trial conditions, which is a decision-support failure rather than an analytical one. Models that reconcile guideline sources, resolve complex diplotypes, account for drug-drug-gene interactions in patients on 5 or more medicines, and surface a recommendation inside the prescribing workflow address the constraint that actually limits adoption, and they attach to the software and services offering rather than to consumables.

The fastest-growing region is the one least well served by existing panel content, which is a commercial opportunity rather than only a scientific gap. Asia-Pacific is projected to register a 10.1% CAGR through 2036, led by China at 11.3%, yet the randomised evidence base was 97.7% European, Mediterranean or Middle Eastern in ancestry. CYP2C19 loss-of-function alleles relevant to clopidogrel and proton pump inhibitor dosing occur at materially higher frequency in East and South Asian populations, HLA-B*15:02 relevant to carbamazepine hypersensitivity is concentrated in Southeast Asian populations, and NUDT15 variants relevant to thiopurine dosing are more common in East Asian populations than the TPMT variants that dominate European panels. Panels designed against local allele frequencies detect more actionable results per test, which improves the clinical yield that payers and health ministries evaluate, and regional sequencing and genotyping capacity in China, Japan, South Korea and India can manufacture and run them.

The evidence that exists is not the evidence payers require, and closing that gap is the central commercial challenge in this market. The PREPARE study produced an odds ratio of 0.70 with a confidence interval of 0.61 to 0.79 across 6,944 patients, but its endpoint was clinically relevant adverse drug reactions within 12 weeks across a mixed drug set, assessed regardless of whether the 69.9% of accepted recommendations were followed. UnitedHealthcare nonetheless restricted multi-gene panel coverage from 1 January 2025 citing insufficient evidence of efficacy. Payer frameworks built for therapeutics expect drug-specific, outcome-specific randomised evidence, which a panel covering 12 genes and dozens of drugs cannot generate economically for each pair. The practical requirement is health-economic evidence at the system level, including avoided hospitalisation and avoided switching, generated inside the payer population, which is slow, expensive and must be repeated per plan.

A pharmacogenomic result delivers value only when it reaches the prescriber at the moment of prescribing, years after the sample was taken, and most health information systems were not designed for that. The requirement is a durable, structured, machine-readable genotype record that persists across encounters and institutions, phenotype translation that updates as guidelines change for the 217 drugs now carrying pharmacogenomic information, and interruptive alerting calibrated to avoid fatigue. The operational evidence shows both the yield and the burden: one health system requiring DPYD testing since 2022 reported 929 critical pharmacogenomic safety alerts and 154 resulting medication changes from more than 5,000 tests, which is a 3% actionable alert rate against a much larger volume of non-actionable results. Building that infrastructure is a software and services undertaking, not a laboratory one, and it is why implementation succeeds in integrated systems and stalls in fragmented ones.

Laboratories and panel developers must plan multi-year investments without knowing what framework will apply. The laboratory developed tests final rule was vacated on 31 March 2025 in American Clinical Laboratory Association v. U.S. Food and Drug Administration, No. 4:24-CV-479, in the Eastern District of Texas, on the ground that the agency exceeded its statutory authority, after it had been due to take effect in May 2025 and would have covered nearly 80,000 tests at almost 1,200 laboratories. The vacatur removes a compliance programme that many laboratories had already begun building, but it does not resolve the underlying question, since legislative proposals to create a diagnostics pathway recur and European in vitro diagnostic regulation applies conformity assessment to assays placed on that market. A panel developer serving both markets therefore designs to the stricter regime while competing against domestic providers that need not.

The persistent constraint identified across the forecast period is that prescribers do not order tests they do not feel competent to interpret. Recommendation acceptance reached only 69.9% in PREPARE despite protocol support, and the distance between a test being available and a test being ordered is wider still in routine practice. The specific barriers are that pharmacogenomic nomenclature using star alleles and diplotypes is unfamiliar to most prescribers, that the two principal guidance sources diverge for the 50 drugs listed in both, that a result arriving after a prescription is written rarely changes it, and that primary care, which accounts for the large majority of antidepressant prescribing, has the least genomics support. Systems that have overcome this have done so by removing interpretation from the prescriber, through pharmacist-led consultation services and automated decision support, with one system completing more than 800 pharmacogenomic consultations alongside its testing programme.

The fastest-moving demand in this market is the test a label requires rather than the panel a clinician may choose. DPYD genotyping before fluoropyrimidine therapy is now called for in United States capecitabine labelling updated in October 2025, with the agency letter dated 3 October 2025, and has been required across the European Union since 30 April 2020 for intravenous fluorouracil, capecitabine and tegafur. Approximately 7% of patients are poor metabolisers in the United States framing, with up to 9% carrying partial dihydropyrimidine dehydrogenase deficiency and up to 0.5% complete deficiency in the European framing, for whom the medicines are contraindicated. Against that, UnitedHealthcare restricted multi-gene panel coverage under commercial and individual exchange plans from 1 January 2025. The practical consequence is that targeted polymerase chain reaction assays, which hold 39.5% of 2026 value, retain assured volume while panels must win coverage case by case.

Test counts and revenue are no longer moving together, which changes how this market must be forecast. Myriad Genetics reported second-quarter 2026 Mental Health volumes of 140 thousand tests, up 4%, on revenue of USD 36.8 million, down 3%, with average revenue per test down 6%. At group level, total volumes of 379 thousand were down 1% while revenue fell 11% to USD 190.7 million and average revenue per test fell 9%, including an USD 11.0 million reduction from changes in estimates of cash collections on prior-period tests. Adjusted gross margin fell from 71.5% to 66.9%, adjusted EBITDA moved from positive USD 14.5 million to negative USD 16.9 million, and adjusted EBITDA guidance was suspended. The forecasting implication is that unit adoption metrics overstate value growth, and that market value depends on reimbursed price and test mix rather than on penetration alone.

Generating a genotype is no longer the hard part of pharmacogenomics. The constraints that limit adoption are interpretive: the regulatory table and consortium guidelines assign different gene associations or dosing implications to the same drug among the 50 drugs listed in both sources; structurally complex loci such as CYP2D6 carry copy number variation, deletions and hybrid alleles that targeted assays resolve poorly; and recommendation acceptance reached only 69.9% in the PREPARE study despite protocol support. Each of these is addressed by software rather than chemistry, which is why clinical decision support integrated with electronic prescribing, durable structured genotype records, guideline reconciliation and drug-drug-gene interaction modelling are the capabilities that determine whether a testing programme succeeds. Sequencing is the fastest-growing technology at an 11.4% CAGR precisely because it generates the data that interpretation layers require, not because detection alone creates clinical value.

Systems that have made pharmacogenomic testing work have done so by removing interpretation from the prescriber. The operational pattern is a pharmacist-led consultation service that receives the result, reconciles guideline sources, reviews the full medication list and issues a dosing recommendation, supported by automated alerting in the electronic record. One United States health system that has required DPYD testing since 2022 reported more than 5,000 oncology tests, 929 critical pharmacogenomic safety alerts, 154 medication changes that prevented serious harm and more than 800 pharmacogenomic consultations completed. The 3% ratio of actionable medication changes to tests performed, and the much larger volume of alerts that did not require change, show why a dedicated interpretive function is necessary rather than optional. For suppliers this shifts the buying centre from the laboratory director to pharmacy and informatics leadership.

This market is being pulled by two authorities with incompatible evidence standards. Drug regulators and guideline bodies have expanded pharmacogenomic recommendations to 217 drugs as of 22 July 2024 and have made DPYD testing a labelling requirement in the United States from October 2025 and in Europe from 30 April 2020. Commercial payers have moved the other way, with UnitedHealthcare restricting multi-gene panel coverage from 1 January 2025 on the ground of insufficient evidence of efficacy, notwithstanding the PREPARE odds ratio of 0.70 with a 95% confidence interval of 0.61 to 0.79 across 6,944 patients. The vacatur of the laboratory developed tests final rule on 31 March 2025 removed the device review that payers might otherwise have relied on. The result is a market in which a test can be simultaneously required by a drug label and excluded from a benefit plan.

Based on offering, the market is segmented into consumables, instruments, and software & services. In 2026, the consumables segment is expected to account for the largest share of the global Pharmacogenomics Market at 71.5%. The large share of this segment is mainly due to the recurring consumption of assay kits, reagents, probes, primers, arrays and library preparation chemistry on an installed instrument base, and to the per-sample economics of mandated single-gene assays such as DPYD genotyping. The consumables segment is also projected to register the fastest growth during the forecast period, at a CAGR of 9.1%, which is attributed to rising test volumes driven by labelling requirements effective from October 2025 in the United States and 30 April 2020 in Europe, and to the shift toward sequencing-based panels interrogating 50 or more variants per sample, which consumes substantially more reagent per test than a targeted assay.

Based on technology, the market is segmented into polymerase chain reaction, sequencing, microarray, mass spectrometry, electrophoresis, and other technologies. In 2026, the polymerase chain reaction segment is expected to account for the largest share of the global Pharmacogenomics Market at 39.5%. The large share of this segment is mainly due to its suitability for targeted genotyping of single actionable variants such as DPYD, HLA-B*57:01 and CYP2C19, where mandated and reimbursed testing is concentrated, and to low cost and rapid turnaround of about a week in treatment planning. However, the sequencing segment is projected to register the fastest growth during the forecast period, at a CAGR of 11.4%. The rapid growth of this segment is attributed to pre-emptive panels requiring 50 germline variants across 12 or more genes, and to resolution of structurally complex loci such as CYP2D6 that targeted assays handle poorly.

Based on test type, the market is segmented into single-gene tests, multi-gene panel tests, and whole exome & whole genome sequencing. In 2026, the single-gene tests segment is expected to account for the largest share of the global Pharmacogenomics Market. The large share of this segment is mainly due to mandated and strongly recommended assays with clear clinical consequences, including DPYD before fluoropyrimidines, HLA-B*57:01 before abacavir, HLA-B*15:02 before carbamazepine, TPMT and NUDT15 before thiopurines, UGT1A1 before irinotecan and G6PD before rasburicase, each of which carries settled reimbursement logic. However, the multi-gene panel tests segment is projected to register the fastest growth during the forecast period. The rapid growth of this segment is attributed to the PREPARE finding that clinically relevant adverse drug reactions fell from 28.6% to 21.5% at an odds ratio of 0.70, and to 93.5% of participants carrying at least one actionable variant.

Based on biomarker, the market is segmented into cytochrome P450 enzymes, DPYD, TPMT & NUDT15, UGT1A1, HLA alleles, SLCO1B1, VKORC1, G6PD, and other biomarkers. In 2026, the cytochrome P450 enzymes segment is expected to account for the largest share of the global Pharmacogenomics Market. The large share of this segment is mainly due to the breadth of drugs metabolised through CYP2C19, CYP2D6, CYP2C9 and CYP3A4 and CYP3A5, which include the antiplatelets, antidepressants, antipsychotics, proton pump inhibitors and immunosuppressants that dominate pre-emptive panel content. However, the DPYD segment is projected to register the fastest growth during the forecast period. The rapid growth of this segment is attributed to the United States capecitabine labelling update of October 2025 calling for testing before initiation unless urgent, and to the European requirement in force since 30 April 2020 across fluorouracil, capecitabine and tegafur.

Based on sample type, the market is segmented into whole blood, buccal swab, saliva, and other sample types. In 2026, the whole blood segment is expected to account for the largest share of the global Pharmacogenomics Market. The large share of this segment is mainly due to the concentration of testing in hospitals and diagnostic laboratories, which hold 62.9% of 2026 value and draw blood as part of routine pre-treatment workup, and to the suitability of whole blood for high-yield DNA extraction supporting panels of 50 or more variants. However, the buccal swab and saliva segments are projected to register the fastest growth during the forecast period. The rapid growth of these segments is attributed to pre-emptive testing moving into primary care and community pharmacy, where phlebotomy is not routinely available, and to self-collection workflows that support population programmes rather than episode-based testing.

Based on application, the market is segmented into oncology, mental health, infectious diseases, cardiology, neurological disorders, pain management, and other applications. In 2026, the oncology segment is expected to account for the largest share of the global Pharmacogenomics Market at 36.0%. The large share of this segment is mainly due to mandated pre-treatment testing in cytotoxic therapy, including DPYD before fluoropyrimidines and UGT1A1 before irinotecan, and to the severity of avoided toxicity, with no safe starting dose established for poor metabolisers. The oncology segment is also projected to register the fastest growth during the forecast period, at a CAGR of 10.6%, which is attributed to the capecitabine labelling update of October 2025 converting a large recurring prescribing population into a testing population, and to health system programmes reporting more than 5,000 oncology tests and 154 preventive medication changes.

Based on end user, the market is segmented into hospitals & diagnostic laboratories, academic & research institutes, pharmaceutical & biotechnology companies, and other end users. In 2026, the hospitals & diagnostic laboratories segment is expected to account for the largest share of the global Pharmacogenomics Market at 62.9%. The large share of this segment is mainly due to the concentration of mandated pre-treatment testing within treatment pathways, the integration of results into institutional electronic prescribing, and the position of reference laboratories as the delivery channel for most pharmacogenomic testing, the majority of which is offered as a laboratory developed test. The hospitals & diagnostic laboratories segment is also projected to register the fastest growth during the forecast period, at a CAGR of 10.2%, which is attributed to labelling requirements effective from October 2025 and to pharmacist-led consultation services, with one system completing more than 800 consultations.

Based on mode of access, the market is segmented into clinician-ordered reimbursed testing, clinician-ordered self-pay testing, and research and pharmaceutical-funded testing. In 2026, the clinician-ordered reimbursed testing segment is expected to account for the largest share of the global Pharmacogenomics Market. The large share of this segment is mainly due to mandated single-gene assays that payers cover because a drug label requires them, and to the position of hospitals and diagnostic laboratories at 62.9% of 2026 value. However, the clinician-ordered self-pay testing segment is projected to register the fastest growth during the forecast period. The rapid growth of this segment is attributed directly to coverage withdrawal, following the UnitedHealthcare restriction on multi-gene panel testing under commercial and individual exchange plans effective 1 January 2025, which leaves patients advised to test with no benefit pathway, and to average revenue per test falling 6% as providers absorb reimbursement loss.